I am curious what your practices might be doing in terms of choice of therapy with a 3rd in class BRAF/MEK inhibitor combo likely coming to market very soon? What factors would sway you to one product over another?

Also- do you think this will help to drive down cost of these oral agents?

Looking forward to everyone’s insights.